Hi, help us enhance your experience
Hi, help us enhance your experience
Hi, help us enhance your experience
963 Views
Dr KK Aggarwal 29 November 2020
With input from Dr Monica Vasudev
1173: Anti-cytokine therapy controls inflammatory bowel disease (IBD) symptoms by normalizing decreased or raised ACE2 levels, and could play a protective role in COVID-19. ACE2 is known to be highly expressed in the bowel.
As per Dr. Dermot P. B. McGovern of Cedars-Sinai Medical Center in Los Angeles, ACE2 expression is altered in IBD and is linked with response to the anti-cytokine drug, infliximab. A paper published in Cell suggests that individuals with COVID-19 have high TNF levels and that mouse models were relatively protected from some of the COVID-19-like manifestations following treatment with neutralizing antibodies to TNF. (https://bit.ly/375VBEa).
A study, published in Gastroenterology, showed reduced small bowel, but raised colonic ACE2 levels in IBD are linked with inflammation and severe disease but normalized following anti-cytokine therapy suggesting compartmentalization of ACE2-related biology in small bowel and colonic inflammation. (https://bit.ly/3kXQPxI)
1174: USA Vaccine picture
1175: No clinical benefit of using convalescent plasma in patients with COVID-19 severe pneumonia
DG Alerts Excerpts: 1. The use of convalescent plasma therapy besides standard treatment in patients with severe pneumonia due to COVID-19 did not decrease mortality or improve other clinical outcomes at day 30, in comparison with placebo, noted a study published in The New England Journal of Medicine.
[https://www.nejm.org/doi/full/10.1056/NEJMoa2031304?query-featured_coronavirus=]
1176: The FDA has authorized the use of a COVID-19 semi-quantitative antibody testing kit that can detect the exact level of IgG antibodies to SARS-CoV-2, stated the test manufacturer. COVID-SeroKlir received emergency use authorization (EUA) for the assay, which identifies SARS-CoV-2-specific IgG antibodies against the full length spike protein and its receptor binding domain with a sensitivity of 98.8% and specificity of 99.6%, Kantaro said. This is a two-step enzyme-linked immunoassay that can be used by any CLIA-certified laboratory with no proprietary equipment needed. (Medpage Today)
Dr KK Aggarwal
President CMAAO, HCFI and Past National President IMA
{{Article_Title}}
{{Article_Author}}
{{Article_Title}}
{{Article_Author}}